Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.
Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.
复制标题
DOI：
10.1158/1078-0432.ccr-21-2372
复制
发表时间：
2022-12-01
影响因子：
11.5
通讯作者：
Brugarolas, James
中科院分区：
文献类型：
--
作者：
Yao, Chen;Zhang, Tian;Wu, Tuoqi;Brugarolas, James
免疫疗法在许多肿瘤中产生了重大影响，包括肾细胞癌（RCC）。自IFNα和IL 2的细胞因子时代以来，已知RCC具有免疫应答，但只有少数患者具有持久的临床益处。从那时起，关键肿瘤驱动因素的发现，以及对血管生成和肿瘤微环境（TME）贡献的了解，推动了药物开发的进步，最终改变了患者的预后。抗血管生成剂与免疫检查点抑制剂的组合现在是护理标准。当前的挑战包括免疫治疗组合的患者选择、耐药性获得和最佳测序治疗。关于RCC生物学、TME和耐药机制的未来发现可能会为下一代疗法铺平道路。
Immunotherapy has made a significant impact in many tumors, including renal cell carcinoma (RCC). RCC has been known to be immunoresponsive since the cytokine era of IFNα and IL2, but only a small number of patients had durable clinical benefit. Since then, discoveries of key tumor drivers, as well as an understanding of the contribution of angiogenesis and the tumor microenvironment (TME), has led to advances in drug development ultimately transforming patient outcomes. Combinations of anti-angiogenic agents with immune checkpoint inhibitors are now standard of care. Current challenges include patient selection for immunotherapy combinations, resistance acquisition and optimally sequencing therapies. Future discoveries about RCC biology, the TME and resistance mechanisms will likely pave the way for the next generation of therapies.
影响因子：
8.8
作者：
Luiten, R M;Coney, L R;Fleuren, G J;Warnaar, S O;Litvinov, S V
通讯作者：
Litvinov, S V
影响因子：
8.8
作者：
Kroesen, B. J.;Buter, J.;Sleijfer, D. Th.;Janssen, R. A. J.;Van Der Graaf, W. T. A.;The, T. H.;De Leij, L.;Mulder, N. H.
通讯作者：
Mulder, N. H.